Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11384229 | 0.98 | KDM4E (0.34) | POLBAPEX1TDP1RAB9ANPC1 | |
| SCHEMBL27951115 | 0.98 | KDM4E (0.34) | POLBAPEX1TDP1RAB9ANPC1 | |
| SCHEMBL17694211 | 0.98 | KDM4E (0.34) | POLBAPEX1TDP1RAB9ANPC1 | |
| SCHEMBL11384206 | 0.98 | KDM4E (0.34) | POLBAPEX1TDP1RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL10726052 | 0.98 | POLB (0.33) | POLBAPEX1TDP1RAB9ANPC1 | |
| SCHEMBL14398568 | 0.93 | — | — | |
| SCHEMBL28000893 | 0.93 | — | — | |
| SCHEMBL242415 | 0.93 | — | — | |
| SCHEMBL6932950 | 0.91 | POLB (0.34) | POLBAPEX1TDP1EGLN1 | |
| SCHEMBL6917077 | 0.91 | POLB (0.34) | POLBAPEX1TDP1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103732059-A | Nuclear hormone receptor modulators | ABBOTT LAB | 2014-04-16 | — | — | CN | claimed |
| US-5302602-A | 5-HETEROCYCLO-ALKYL SUBSTITUTED DIBENZO (A,D) CYCLOHEPTENES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-04-12 | — | — | US | claimed |
| CN-113896669-B | Estrogen receptor modulators and uses thereof | 海南先声再明医药股份有限公司 | 2024-12-17 | — | — | CN | disclosed |
| US-20230341777-A1 | RESIST UNDERLAYER FILM-FORMING COMPOSITION CONTAINING TERMINAL-BLOCKED REACTION PRODUCT | NISSAN CHEMICAL CORPORATION (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230296984-A1 | EUV RESIST UNDERLAYER FILM-FORMING COMPOSITION | NISSAN CHEMICAL CORPORATION (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20230259028-A1 | RESIST UNDERLAYER FILM-FORMING COMPOSITION CONTAINING REACTION PRODUCT OF HYDANTOIN COMPOUNDS | NISSAN CHEMICAL CORPORATION (JP) | 2023-08-17 | — | — | US | disclosed |
| CN-113896669-A | Estrogen receptor modulators and uses thereof | 江苏先声药业有限公司 | 2022-01-07 | — | — | CN | disclosed |
| CN-103732059-A | Nuclear hormone receptor modulators | ABBOTT LAB | 2014-04-16 | — | — | CN | disclosed |
| EP-2685821-A1 | NUCLEAR HORMONE RECEPTOR MODULATORS | AbbVie Inc. (US) | 2014-01-22 | — | — | EP | disclosed |
| WO-2012125797-A1 | NUCLEAR HORMONE RECEPTOR MODULATORS | ABBOTT LABORATORIES (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20070060592-A1 | heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation | MILLENNIUM PHARMACEUTICALS, INC. | 2007-03-15 | — | — | US | disclosed |
| EP-1562954-A1 | CCR1 ANTAGONISTS FOR THE TREATMENT OF I.A. DEMYELINATING INFLAMMATORY DISEASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1448566-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2004043965-A1 | CCR1 ANTAGONISTS FOR THE TREATMENT OF I.A. DEMYELINATING INFLAMMATORY DISEASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2003045942-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| US-5302602-A | 5-HETEROCYCLO-ALKYL SUBSTITUTED DIBENZO (A,D) CYCLOHEPTENES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-04-12 | — | — | US | disclosed |
| EP-0351887-A1 | Tricyclic aromatic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060592-A1 | heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation | THPO, NFATC1, HPGDS | POLB 903/4885APEX1 1764/4885TDP1 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.